Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
Completed
Pfizer
Phase 3
2003-10-01
This Phase 3 trial will investigate the efficacy, tolerability and safety of fesoterodine
fumarate (SR) (fesoterodine; SPM 907) in adult male and female subjects with overactive
bladder syndrome. The trial is a randomized, double-blind placebo controlled multicenter
trial.
The trial consisted of a 2 week Run-In period, 12 week double-blind Treatment period and 2
week Safety Follow-Up period. Subjects were randomized to one of 3 treatment arms receiving
either fesoterodine fumarate 4mg, fesoterodine fumarate 8mg, or placebo during the
double-blind Treatment period.
Two primary efficacy variables will be assessed for submission in the United States: change
in the average number of micturitions (frequency) per 24 hours and the change in the average
number of urge incontinence episodes per 24 hours. For the submissions in the European Union,
the first primary variable will be the change in the average number of micturitions
(frequency) per 24 hours and the co-primary variable is the treatment response, based on a
treatment benefit scale. All continuous variables will be measured as changes from baseline
to value after 12 weeks of treatment. The following safety variables were observed and
assessed: adverse events, change in residual urinary volume (mL), change in laboratory
parameters, change in vital signs, change in electrocardiogram (ECG), change in physical
examination and change in urological/urogynecological examination.
A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
Completed
Pfizer
Phase 3
2007-01-01
To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB)
symptom relief in OAB patients who were dissatisfied with their prior therapy with
tolterodine.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
